Prostatype Genomics AB (publ) (STO:PROGEN)
Sweden · Delayed Price · Currency is SEK 0.0970
-0.0014 (-1.42%)
Aug 13, 2026, 5:20 PM CET
Prostatype Genomics AB Revenue
In the year 2025, Prostatype Genomics AB had annual revenue of 597.00K SEK, down -69.89%. Prostatype Genomics AB had revenue of 351.00K in the half year ending December 31, 2025, a decrease of -87.12%.
Revenue
597.00K
Revenue Growth
-69.89%
P/S Ratio
9.81
Revenue / Employee
84.86K
Employees
7
Market Cap
5.82M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 597.00K | -1.39M | -69.89% |
| Dec 31, 2024 | 1.98M | -1.80M | -47.64% |
| Dec 31, 2023 | 3.79M | 3.10M | 454.47% |
| Dec 31, 2022 | 683.00K | -1.84M | -72.92% |
| Dec 31, 2021 | 2.52M | 1.27M | 101.64% |
| Dec 31, 2020 | 1.25M | -1.58M | -55.81% |
| Jun 30, 2020 | 2.83M | -478.21K | -14.45% |
| Jun 30, 2019 | 3.31M | -1.51M | -31.41% |
| Jun 30, 2018 | 4.82M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 34.24B |
| Swedish Orphan Biovitrum AB | 30.62B |
| Sectra AB | 3.65B |
| Camurus AB | 2.27B |
| Magle Chemoswed Holding AB | 273.25M |
| S2Medical AB | 16.13M |
| Luxbright AB | 13.75M |
| Aptahem AB | 2.52M |
Prostatype Genomics AB News
- 6 months ago - Prostatype Genomics AB Quarterly report: Q4 2025 - Filings
- 6 months ago - Prostatype Genomics AB Annual report: Q4 2025 - Filings
- 9 months ago - Prostatype Genomics AB Transcript: Life Science Summit 2025 - Transcripts